Switch to
More onapp

How to use scorecard? Learn more

Chandra Bhagat Pharma Ltd

CBPL
Health CareHealth Care Distributors
SmallcapWith a market cap of ₹51 cr, stock is ranked 3,474
High RiskStock is 6.04x as volatile as Nifty
64.000.00 (+0.00%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareHealth Care Distributors
SmallcapWith a market cap of ₹51 cr, stock is ranked 3,474
High RiskStock is 6.04x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
PB RatioPB Ratio
1.78
Dividend YieldDiv. Yield
Sector PESector PE
51.22
Sector PBSector PB
6.55
Sector Div YldSctr Div Yld
0.48%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Chandra Bhagat Pharma Ltd is an India-based medicine company. The Company is engaged in the business of marketing pharmaceutical formulation and products in domestic and international markets through its distribution network and sales force under its own brand. It provides a range of products portfolio of a pharmaceutical formulation including injections (ampoules, vials, prefilled syringe, lyophilized vials), tablet, capsules and oral syrup. The Company’s products include for the domestic market mufost, mufost, herzovir, herzovir, clauvmentin, falsun, azap, azocin, chinofen, polodyl, casfungen, cbtaz, nuperazone, nuperazone forte, nuperazone plus, nuperazone 3g, cefzidime tz, cefzidime, cezoneplus, cezone tz, myocholine, klarinton, samcy, dobier s, maxiparine, antacer, cbfos, thionine, thromboparin, meplife combipack, merospect and norepirin.

Financial TrendFinancial statements 

202120222023202471.1895.70119.96232.700.200.800.901.51
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

AGM/EGM 
Announced OnOct 2, 2024

Chandra Bhagat Pharma Ltd - 542934 - Voting Result | Download

Chandra Bhagat Pharma Ltd - 542934 - Voting Result | Download

AGM/EGM 
Announced OnOct 2, 2024

Chandra Bhagat Pharma Ltd - 542934 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | Download

Chandra Bhagat Pharma Ltd - 542934 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | Download

Insider Trading / SAST 
Announced OnOct 1, 2024

Chandra Bhagat Pharma Ltd - 542934 - Closure of Trading Window | Download

Chandra Bhagat Pharma Ltd - 542934 - Closure of Trading Window | Download

See all events